Michael Sullivan
Andreas Hofmann
Racha Majed
Racha has a PhD in microbiology from France, and moved to England to pursue a postdoc at University of Cambridge for 3 years and started with Refeyn over a year as a Technical Sales Specialist.
Jonathan Gast
Markus Müllner
Markus is the CSO at Celeris Therapeutics, an AI-first drug discovery startup from Graz, Austria that aims to discover novel bivalent degraders based on our Celeris One computational platform. Prior to Celeris he was the Chief Technology Officer and head of R&D at PhoreMost, a Cambridge UK Biotech with a novel target discovery platform to drug previously undruggable targets. Markus has a background in engineering, IT and Life sciences. He has a PhD from the Medical University of Vienna (Medical Chemistry) that was followed by a postdoc at the Center for Molecular Medicine (CeMM) with BROAD institute alumni Sebastian Nijman.
Jutta Blank
Jutta holds a degree and PhD in Biochemistry from the University of Bayreuth Germany. Her postdoctoral research was on protein structure and function, first at the MRC Laboratory for Molecular Biology in Cambridge UK and subsequently at AstraZeneca in Alderley Park, UK. After four years at the Syngenta Research Centre as a group leader for target based lead discovery, she moved to Basel to join the Novartis Drug Discovery Centre. Over the years, she gained extensive experience in early Drug discovery. She is currently a director in the department of Chemical Biology and Therapeutics at Novartis in Basel.
Andreas Langer
Andreas Langer has a background in biophysics. He earned his Ph.D. from the Technical University of Munich, Germany, studying electro-switchable biosurfaces and their application in protein analysis. Andreas has 10+ years of experience in the field of molecular interactions and as Principal Scientist at NanoTemper is currently working on the continuous improvement of existing products, as well as the development of new technologies.
